首页> 外文OA文献 >PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

【2h】

PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

机译：PAR12 ABATACEPT（CTLA4IG）与甲氨蝶呤的结合表明，对甲氨蝶呤的反应不足的类风湿关节炎患者两年来持续改善的患者报告的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Li T; Maclean R; Nuamah I; Becker J;
展开▼
作者单位

展开▼
年度 2005
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone† [J] . Patrick Garnero, Elizabeth Thompson, Thasia Woodworth, Arthritis & Rheumatism . 2010,第1期

机译：类风湿关节炎对甲氨蝶呤反应不佳的抗白细胞介素6受体抑制剂托珠单抗加甲氨蝶呤对骨骼和软骨转换指标的快速和持续改善：多西环素双盲，安慰剂对照多中心研究的亚组研究结果甲氨蝶呤反应不足的患者中†
2. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone [J] . GarneroP., ThompsonE., WoodworthT., Arthritis and Rheumatism . 2010,第1期

机译：类风湿关节炎对甲氨蝶呤反应不足的患者，使用抗白细胞介素6受体抑制剂托珠单抗加甲氨蝶呤能快速，持续地改善骨和软骨转换指标：多西环素双盲，安慰剂对照多中心研究的亚组研究结果对甲氨蝶呤的反应不足者
3. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial [J] . Vibeke Strand, Mark Kosinski, Chieh-I Chen, Arthritis research & therapy. . 2016,第1期

机译：Sarilumab联合甲氨蝶呤改善了活动性类风湿关节炎患者对甲氨蝶呤反应不足的患者报告的结果：一项III期试验的结果
4. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial [O] . Vibeke Strand, Mark Kosinski, Chieh-I Chen, 2016

机译：Sarilumab联合甲氨蝶呤改善了活动性类风湿关节炎患者对甲氨蝶呤反应不足的患者报告的结果：一项III期试验的结果
5. PMS37 THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM [O] . Lebmeier M, Pericleous L, Drost P, 2010

机译：PMS37联合使用甲氨蝶呤与甲氨蝶呤治疗在英国对甲氨蝶呤反应不足的患者治疗活动性类风湿关节炎的成本效益

PAR12 ABATACEPT (CTLA4IG) IN COMBINATION WITH METHOTREXATE DEMONSTRATES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OVER TWO YEARS IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

著录项

引文网络

相似文献

相关主题

期刊订阅